<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19874">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02848170</url>
  </required_header>
  <id_info>
    <org_study_id>CS3150-A-J303</org_study_id>
    <nct_id>NCT02848170</nct_id>
  </id_info>
  <brief_title>Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension</brief_title>
  <official_title>An Exploratory Study of CS-3150 to Evaluate the Relation Between Antihypertensive Effect and Baseline Factors Compared to Olmesartan Medoxomil in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 3 study to examine the relation between antihypertensive effect and baseline factors
      exploratively, compared to olmesartan medoxomil in patients with essential hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in 24 hr blood pressure</measure>
    <time_frame>baseline to end of Week 12</time_frame>
    <description>Relationship between the change from baseline in 24 hr blood pressure (systolic, diastolic, and average blood pressure) and baseline factors frpm baseline to end of Week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline in morning, evening, and night blood pressure.</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>Relationship between the change from baseline in morning, evening, and night blood pressure (systolic, diastolic, and average blood pressure) and baseline factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in sitting blood pressure</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>Relationship between the change from baseline in sitting blood pressure (systolic, diastolic, and average blood pressure) and baseline factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of 24 hr blood pressure and sitting blood pressure</measure>
    <time_frame>week 12</time_frame>
    <description>Time course of 24 hr blood pressure and sitting blood pressure (systolic, diastolic, and average blood pressure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving 24 hr and sitting blood pressure control</measure>
    <time_frame>week 12</time_frame>
    <description>Proportion of patients achieving 24 hr and sitting blood pressure control</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>CS-3150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS-3150 2.5 to 5mg, orally, once daily after breakfast for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olmesartan medoxomil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>olmesartan medoxomil 10 to 20 mg, orally, once daily after breakfast for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-3150</intervention_name>
    <description>CS-3150 2.5mg, oral</description>
    <arm_group_label>CS-3150</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil</intervention_name>
    <description>olmesartan medoxomil 10 mg, oral</description>
    <arm_group_label>olmesartan medoxomil</arm_group_label>
    <other_name>Benicar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects aged 20 years or older at informed consent

          -  Subjects with essential hypertension during run-in period (mean 24hr systolic blood
             pressure SBP ≥ 130 and diastolic blood pressure DBP ≥ 80 mmHg and Sitting SBP ≥ 140
             mmHg and &lt; 180 mmHg, Sitting DBP ≥ 90 mmHg and &lt; 110 mmHg)

        Exclusion Criteria:

          -  Secondary hypertension or malignant hypertension

          -  Diabetes mellitus with albuminuria

          -  Serum potassium level &lt; 3.5 or ≥ 5.1 mEq/L

          -  Reversed day-night life cycle including overnight workers

          -  eGFR &lt; 60 mL/min/1.73 m^2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 20, 2017</lastchanged_date>
  <firstreceived_date>July 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>essential hypertension</keyword>
  <keyword>mineralocorticoid receptor antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
